Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams|
- New MRI Technologies [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Assessment of the new technologies will be quantified by a variety of performance and image quality/content measures. The appropriate set of measures will be selected based on specific features offered by each assessed technology, but will be drawn from the following quantities:
- Scan speed: Scan speed is time required to set-up and run the new technique relative to the standard method.
- Signal to noise: SNR (signal to noise ratio)is the ratio of average image intensity in target tissue relative to standard deviation of background areas (outside of body). This is a fundamental parameter used to quantify relative performance of new imaging sequences/hardware/software.
- Contrast to noise: CNR (contrast to noise)is the difference in average image intensity between two target tissues relative to noise. This is a key descriptor to quantity lesion/tissue conspicuity, thus is used to characterize relative performance of new imaging sequence/hardware/software.
|Study Start Date:||January 2009|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
Experimental: Group 2
Subjects will have Additional sequences and/or modification to MRI sequences.
Active Comparator: Group 1
Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinicalliy ordered MRI
Please refer to this study by its ClinicalTrials.gov identifier: NCT00727792
|United States, Michigan|
|University of Michigan Hospital|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Jadranka Stojanovska, MD||University of Michigan|